The Alzheimer’s Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer’s Disease
LA JOLLA, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that it has been awarded a grant to receive $1,000,000 from the Alzheimer's Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease. The endowment was awarded under the Part the Cloud to RESCUE grant. The $1,000,000 award will be paid to the Company in traches over the course of the Phase 1 clinical trial.
“We are honored to receive this grant from the Alzheimer’s Association,” said RJ Tesi, M.D., CEO of INmune Bio. “The Alzheimer’s Association has shown the vision and leadership to support the quest for effective therapies beyond traditional targets. As an immunology company, we focus on the role that innate immune dysregulation and neuroinflammation play in the progression of Alzheimer’s. This grant allows us to enter clinical trials – something that would not have been possible without the organization’s generous support.”
“Today, 50 million people worldwide are living with Alzheimer’s and related dementias, a truly astounding number that continues to grow with the aging global population,” said CJ Barnum, Ph.D., Director of Neuroscience for INmune Bio. “XPro1595 has been shown to inhibit microglial activation, part of the pathophysiology of neuroinflammation, in animal models of neurodegenerative disease. This Phase I trial will translate those findings into patients.” For more information about the Part the Cloud grants, please visit: https://www.alz.org/partthecloud/overview.asp
For more information about the Alzheimer’s Association, please visit:
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors. To learn more, please visit www.inmunebio.com.
INmune Bio Contact:
David Moss, CFO
Ascent Investor Relations:
LHA Investor Relations
Miriam Weber Miller
Senior Vice President